Efficacy and Safety of Polyoxidonium in Hospitalized Patients With Coronavirus Disease COVID-19

  • STATUS
    Recruiting
  • participants needed
    394
  • sponsor
    NPO Petrovax
Updated on 19 February 2024
ct scan
mechanical ventilation
covid-19
chest x-ray
SARS
coronavirus infection
acute respiratory syndrome (sars)

Summary

The purpose of this study is to demonstrate the superiority of Polyoxidonium, lyophilizate for solution for injections and topical application, 6 mg over placebo in hospitalized patients with coronavirus disease (COVID-19). This is a multicentre prospective, randomized, double-blind, placebo-controlled, parallel-group phase IIb\IIIa clinical trial.

Description

This is a multicenter prospective, randomized, double-blind, placebo-controlled, parallel-group phase 3 IIb\IIIa trial to evaluate the efficacy of Polyoxidonium, lyophilizate for solution for injections and topical application, 6 mg over placebo in hospitalized patients with coronavirus disease (COVID-19). A study will last for 293 days (maximum) for each participant and will include: screening (days -1...1); treatment period (17 days in total, days 1...17) with the administration of the investigational product Polyoxidonium/placebo (intravenous injections for 3 days, then intramuscular injections for 14 days), assessment of the clinical status, recording of AEs; follow-up period (days 18...293).

Haematology and blood chemistry tests will be performed at day -1 and days 1,3, 8 1, 171.

Assessment of the clinical status according to the 7-point ordinal scale and according to the National Early Warning Score (NEWS) scale will be done every day during hospitalization from day 1 up to and including day 17 and at the follow-up on day 293.

The safety and tolerability will be evaluated throughout the study (from signing the Informed Consent Form to the study completion visit).

Details
Condition Coronavirus Infection
Age 18years - 85years
Treatment Placebo, azoximer bromide
Clinical Study IdentifierNCT04381377
SponsorNPO Petrovax
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Male and female patients from 18 to 85 years of age
The patient (or his/her legal representative, if the patient is not able to sign the form) signed an Informed Consent form for participation in this study before any initiation of any study procedures
The patient can understand all protocol requirements, perform the study procedures, and agree to all limitations specified in the protocol
Confirmed diagnosis of coronavirus disease (COVID-19): laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen < 14 days prior to randomization
Illness (coronavirus disease COVID-19) of any duration, and at least one of the
following
Radiographic/tomographic chest infiltrates by imaging (chest x-ray, CT scan, etc.), OR
Evidence of rales/crackles on clinical exam AND SpO2 94% on room air, OR
Indications for mechanical ventilation and/or supplemental oxygen
Agrees to use adequate contraception methods (the methods with at least 90% efficacy include non-hormonal intrauterine devices; condom with intravaginal spermicide; cervical caps

Exclusion Criteria

History of clinically significant allergic reactions
Hypersensitivity and/or intolerability to any ingredient of the investigational product or placebo
Anticipated transfer to another hospital which is not a study centre within the next 72 hours
Acute or chronic renal failure
History of HIV infection, tuberculosis
Conditions associated with primary immunodeficiency
Concomitant use of cytostatic medications to treat a concomitant disease
Systemic connective tissue diseases
Need for the prohibited medications
Administration of medications that are prohibited or unauthorized by the protocol within 2 weeks before the expected randomization date
History of alcohol or drug dependence
History of malignant tumours of any location with remission for less than 2 years
History of psychic (including depressive) disorders, physical and other factors that do not allow for adequate self-assessment of one's behaviour and for compliance with the protocol requirements, including history of psychiatric disorders
Pregnancy or breastfeeding
Intravenous injections and/or sampling of the required amount of blood is not possible
Positive pregnancy test (in patients with childbearing potential)
Participation in any clinical study within 3 months before enrolment in this study
History of any condition that the study doctor considers significant enough to prevent enrolment of this patient
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.